Slaughter and May is advising Oxford Nanopore Technologies plc (“Oxford Nanopore”) on its initial public offering (the “Offer”).
Headquartered in the UK, Oxford Nanopore has developed and commercialised a new technology platform, using nanopore-based sensing for the analysis of a range of types of molecules. Its first products are designed to deliver accessible, rapid, data-rich, DNA/RNA analysis and are used in scientific applications including biomedical/cancer research and plant, animal, pathogen and environmental analyses.
The offer price of 425 pence per ordinary share will give Oxford Nanopore a market capitalisation of approximately £3.4 billion at the commencement of conditional dealings on the Main Market of the London Stock Exchange on 30 September 2021. Admission of the ordinary shares to the standard listing segment of the Official List is expected to occur on 5 October 2021, with unconditional dealings in the shares commencing on the same day.
The Offer comprises a primary offer of new shares to be issued by Oxford Nanopore, which is expected to raise gross proceeds of approximately £350 million, together with a secondary offer of existing shares to be sold by certain existing shareholders equating to a total Offer size of approximately £524 million.
Paul, Weiss, Rifkind, Wharton & Garrison LLP is advising on matters of US law.
Kudrat Agrawal / Trainee, Claire Hooi / Trainee, Patrick Garrett / Trainee, Miles Mason / Trainee, Shanuk Mediwaka / Trainee, Elizabeth Oladunni / Trainee, Ben Moule / Trainee, Annabelle Sharp / Trainee, Holly Southey / Trainee